Novartis, Entresto
Digest more
Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first ...
The stock is down on a predictable, already-announced Entresto patent cliff (Entresto -42% YoY in Q1) and the market is ...
Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on Novartis to offset those lost sales with newer drugs or dealmaking, the report said.
As blockbuster heart failure drug Entresto inches toward a patent cliff, Novartis is calling on the FDA—again—to keep early-bird generics at bay. At the time, Novartis argued greenlighting any ...
Novartis Q1 2026 earnings missed as generic competition hit Entresto sales; Kisqali and Pluvicto growth offsets.
Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as ...
Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results